The pandemic forced clinical trial sponsors to change their processes, with a more technology-driven approach and, according to a new study by Medidata, the sector is now “stronger than ever” as a result.
The study, based on interviews conducted earlier this year with 400 clinical trial executives from the UK, France, Germany, and Switzerland, found that more than a third (37%) ranked better outcomes of trials within the top three areas of improvement since COVID-19 emerged.
